Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events

Abstract

MPA is clinically administered as morfolinoethyl ester (mycophenolate mofetil, MMF) or, more recently, as a salt (enteric-coated mycophenolate sodium). It is a fermentation product of Penicillium brevicompactum and other analogue fungi, identified by Gosio in 1893 as a weak antibacterial agent; in 1969 Franklin and Cook discovered its capacity to inhibit the inosine mono phosphate dehydrogenase (IMPDH), an enzyme involved in purine nucleotide synthesis (1)...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Reviews
Statistics
  • Abstract views: 925

  • PDF: 900
How to Cite
Zizzo, G., De Santis, M., & Ferraccioli, G. (1). Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events. Reumatismo, 62(2), 91-100. https://doi.org/10.4081/reumatismo.2010.91

Most read articles by the same author(s)